- Home
- MTVA vs EQS Comparison
MTVA vs EQS Comparison
Compare MTVA & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- EQS
- Stock Information
- Founded
- MTVA 2014
- EQS 1991
- Country
- MTVA United States
- EQS United States
- Employees
- MTVA N/A
- EQS N/A
- Industry
- MTVA
- EQS Finance Companies
- Sector
- MTVA
- EQS Finance
- Exchange
- MTVA NYSE
- EQS Nasdaq
- Market Cap
- MTVA 16.8M
- EQS 17.0M
- IPO Year
- MTVA N/A
- EQS N/A
- Fundamental
- Price
- MTVA $1.60
- EQS $1.37
- Analyst Decision
- MTVA Strong Buy
- EQS
- Analyst Count
- MTVA 1
- EQS 0
- Target Price
- MTVA $12.00
- EQS N/A
- AVG Volume (30 Days)
- MTVA 23.0K
- EQS 3.4K
- Earning Date
- MTVA 03-27-2025
- EQS 01-01-0001
- Dividend Yield
- MTVA N/A
- EQS N/A
- EPS Growth
- MTVA N/A
- EQS N/A
- EPS
- MTVA N/A
- EQS N/A
- Revenue
- MTVA N/A
- EQS $1,137,000.00
- Revenue This Year
- MTVA N/A
- EQS N/A
- Revenue Next Year
- MTVA N/A
- EQS N/A
- P/E Ratio
- MTVA N/A
- EQS N/A
- Revenue Growth
- MTVA N/A
- EQS 1795.00
- 52 Week Low
- MTVA $1.51
- EQS $1.01
- 52 Week High
- MTVA $6.75
- EQS $1.63
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- EQS 58.36
- Support Level
- MTVA N/A
- EQS $1.26
- Resistance Level
- MTVA N/A
- EQS $1.43
- Average True Range (ATR)
- MTVA 0.00
- EQS 0.05
- MACD
- MTVA 0.00
- EQS -0.00
- Stochastic Oscillator
- MTVA 0.00
- EQS 69.29
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.